FLT3 and acute myeloid leukemia: First, FLT3 inhibition has significantly improved outcomes in FLT3-mutated AML across the treatment continuum: midostaurin, when added to 7 + 3 chemotherapy, improved overall survival (OS) in newly diagnosed patients (Stone et al., 2017; Wang P. et al., 2024; Döhner et al., 2022).